The FDA has granted accelerated approval to Opdivo (nivolumab) injection for intravenous use for the treatment of patients with hepatocellular carcinoma (HCC).
Indications: Opdivo is a programmed death receptor-1 blocking antibody indicated for the treatment of patients with HCC who have been previously treated with sorafenib.
Dosage and administration: 240 mg every 2 weeks.
Efficacy and safety: Approval is based on results from a phase 1/2 open-label study showing that 14% of patients responded to treatment with Opdivo.
Side effects/risks: The most common adverse reactions are fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, and pyrexia.
Bristol-Myers Squibb’s Opdivo (nivolumab) receives FDA approval for the treatment of hepatocellular carcinoma patients previously treated with sorafenib [news release]. Princeton, NJ: Bristol-Myers Squibb Company. September 22, 2017. https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-re.... Accessed October 1, 2017.
Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2017. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed October 1, 2017.
This Week's Must Reads
Durvalumab Post-Chemoradiotherapy in NSCLC Assessed, N Engl J Med; ePub 2017 Sep 8; Antonia, et al
Cochrane on Detecting CRC in Patients with IBD, Cochrane; 2017 Sep 18; Bye, Nguyen, Parker, et al
Lymph Node Removal During Endometrial Ca Surgery, Cochrane; 2017 Oct 2; Frost, Webster, et al
Cochrane on Reducing Neoplasia in Molar Pregnancy, Cochrane; 2017 Sep 11; Wang, Fu, Hu, et al
Cochrane on Reconstructing the Pancreatic Stump, Cochrane; 2017 Sep 12; Cheng, Briarava, et al
Must Reads in FDA Actions
FDA Approves Keytruda for Advanced Gastric Ca, Merck news release; 2017 Sep 22
FDA Approves Opdivo for Hepatocellular Carcinoma, Bristol-Myers Squibb news release; 2017 Sep 22
New Indication for Somatuline Depot, Ipsen package insert; 2017 Sep
Verzenio Approved for Certain Breast Cancers, FDA news release; 2017 Sep 28
FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14